Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of dosing with mipomersen
for 26 weeks in patients with high cholesterol who are on a maximally tolerated dose of
statin and who have a diagnosis that puts them at least at high risk of coronary heart
disease (CHD).